Transcript Document
Financing HIV/Aids in South Africa and role of major donors Meeting to inform Council for Foreign Relations January 2010 Mark Blecher National Treasury Keith Cloete WC DOH Scale of problem • SA has largest number of HIV infected persons in world >5m • Largest number of persons on treatment • Number of persons on treatment growing rapidly – will exceed 400 000 pa in 10/11 • Soon to exceed 1 mil on treatment but this will grow to over 3 million • 400 000 new infections pa with prevention programmes not sufficiently effective • Highest spending of any country on HIV ….but this will need to triple over time • Huge implications for struggling health services 2 HIV costing • NSP costing suggested scenarios of R11b-R13b per annum by 2011 • New draft costing by aids2031 suggest costs could reach R40 billion by 2030 • This includes other sectors and private – but amounts are huge – could rise from 18% to 40% of health budget • And these don’t fully factor costs of lower treatment threshold of cd4 350 • Need to continue to strive to reduce unit costs 3 NSP: Summarized total costs for the low cost scenarios (million Rands, 2005/06 prices) Year Priority area Prevention Goal intervention Reduce sexual transmission Behavioural change interventions Condom provision Life skills PEP for sexual assault STI management Reduce transmission through occupational exposure PEP for occupational exposure Care, support and health system strengthening Scale-up access to VCT HIV testing Maintain health of HIV-infected adults Antiretroviral treatment for adults Food support for adults Home and Community Based Care Address the special needs of mothers and children Antiretroviral treatment for children OVC PMTCT dual therapy and infant testing Strengthen the health system Strengthen TB programme management Increase CHC coverage Grand Total 2007 643 2008 792 2009 951 2010 1,098 2011 1,247 % Total 12% 642 300 145 158 10 30 1 1 790 400 152 168 10 60 1 1 949 500 172 177 11 90 1 1 1,097 600 180 186 11 120 1 1 1,245 700 188 195 12 150 1 1 12% 6% 2% 2% 0% 1% 0% 0% 4,042 5,612 6,960 8,474 10,012 88% 260 260 2,495 1,588 521 386 1,007 245 452 310 280 30 250 420 420 3,365 2,296 586 483 1,267 359 561 348 560 60 500 423 423 4,250 3,115 652 483 1,447 488 589 370 840 90 750 426 426 5,301 4,036 782 483 1,627 635 618 374 1,120 120 1,000 428 428 6,360 5,014 912 435 1,823 791 649 383 1,400 150 1,250 5% 5% 55% 40% 9% 6% 18% 6% 7% 4% 11% 1% 9% 4,685 6,404 7,910 9,572 11,259 100% 4 Aids 2031 Draft scenario Aids 2031 Draft scenario Projected growth in number of ART patients if 80% target is met (Dorrington) 3 500 000 3 000 000 2 500 000 2 000 000 1 500 000 1 000 000 500 000 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 0 Financing • Both graphs (cost and number of arvs) level off • Once level off govt can fully carry costs • However period from 2010 to 2015 is one of v rapid scale-up • Esp given lower treatment thresholds, move to 80% coverage, improved prevention …..and many other health sector issues and priorities • Require >R2bil new funds annually during scale-up • Difficult to sustain this level of scale-up and simultaneously replace existing donor funding 8 Some major financing streams 09/10 approximate R million HIV and AIDS conditional grant Provincial own contributions National Department of Health (core) Health: CG+prov own+nat own Education CG Social Development Subtotal PEPFAR Global fund and other donors Provinces - hospital and PHC care Total 09/10 4,376 1,077 500 5,053 177 678 6,631 4,314 1,000 5,000 17,631 9 Two broad positions of donors 1) Middle income countries must look after themselves or 2) Very high burden of disease middle income countries merit support • We support second option. SA has little need for donors beyond HIV, but the HIV problem is very large and difficult • Sustainable as govt will take over funding as treatment numbers start stabilising • Govt has sought partnership with major donors eg PEPFAR and Global Fund 10 Major donors • Pepfar and Global Fund have played major role in SA • Especially helped to build capacity through supporting govt treatment points • Supported large numbers of worthy projects • Amounts are large and partnership is valuable • Donors potentially bring technical expertise, flexibility, support 11 Problem areas • Value for money huge amounts being spent – are we getting best value – we may have sufficient funds if we optimally used the combined pool • Weak coordination between provincial and donor funded services • Fragmentation between large numbers of organisations poorly coordinated • Difficulty aligning services and funding coming via multiple routes • Difficulty allocating tasks and funding around a common plan 12 Potential improvements • Build shared commitment around common plan and agreement on division of work –responsibilities, services and funding • Funding on budget (WC Global Fund) worked v well • Would be good to develop a five year plan and clear partnership (there is huge amount to do – scale up to 3 m on Rx) 13 Western Cape case study Scenarios for uptake of ART in the Western Cape Province (assuming guideline change for ART eligibility to 350 cells/µl) 40,000 Total New S4 and starting ART 35,000 30,000 25,000 20,000 15,000 Current financial year 10,000 New Stage IV - public sector estimate Actual provision Roundtable scenario National model for policy change to CD4 350 Current trajectory following roundtable scenario 5,000 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Background • The Current (Expiring) Western Cape GF Grant Programme – – Round 3 (originally 5-year grant) Sub-CCM: Western Cape Provincial AIDS Council • Title: Strengthening & Expanding the Western Cape HIV/AIDS Prevention, Treatment & Care Programme • Four Objectives in the Grant Programme 1. 2. 3. 4. • ARV treatment services Peer education HIV prevention intervention in selected secondary schools Palliative care services Community Based Response (small grants programme to local CBOs/NGOs) Special circumstances of Western Cape Phase 2 Grant Programme – 4-year Phase 2 period in respect of Objectives 1 & 3 in order to provide for a Grant exit strategy (funding ends June 2010) – 3-year Phase 2 period in respect of Objectives 2 & 4 (funding ended June 2009) ARV Treatment Services – Western Cape • Costing Model – Revised normative staffing model for medical, nursing, pharmacy, clerical & adherence support (NGO) staff • Task shifting/sharing • First year’s treatment norms vs norms for subsequent years • 2009 public service salary scales + 7% inflator p.a. – Revised model for patients on first & second line ARV treatment • All patients start on first line • Average of 0.2% per month changed to second line – Average ARV medicine cost/patient • In 2009: First line: R215 p.m.; Second line: R642 p.m. • Constant unit cost/patient over RCC period – Lab tests (NHLS): CD4 Count & Viral Load • 6 monthly tests per patient (ART Protocol) • Average 5% p.a. inflator over RCC period W CAPE RCC PROPOSAL DEVELOPMENT • Addressing Long Term Financial Sustainability – Government’s ability to meet the funding requirements of the Western Cape HIV/AIDS Programme (from own revenue sources) has been seriously affected by the global economic downturn since 2008. – Problem is likely to persist over the coming MTEF period, followed by economic & fiscal recovery. – RCC Proposal is therefore structured in order to: • Request maximum possible Grant funding for Years 7 – 9 • Followed by incremental transfer of Grant Programme activities to government funding sources in Years 10 – 12 Conclusion • HIV treatment and prevention will need to scale up massively over next 5 -10 years • This has huge cost implications – spending doubling to tripling • However ultimately sustainable as numbers and costs level off • Partnership and support will be valuable during this period of rapid scale-up • There are many advantages to developing an improved partnership arrangement over next 5+ years • We value support that has been given and would hope to see an ongoing and strengthened partnership for next 5 years 19